GlaxoSmithKline’s investigational therapy belantamab mafodotin has been recommended for approved in the European Union, by the Committee for Medicinal Products for Human Use (CHMP), for heavily treated multiple myeloma patients. The marketing authorization application, accepted for review in February, is specific for people with relapsed or refractory disease who were previously treated with an immunomodulatory agent, a proteasome inhibitor, and a CD38-targeting antibody. Of note, refractory cancer, or resistant cancer, does not respond to treatment. Opinions released by the…
You must be logged in to read/download the full post.
The post EU Approval Urged for GSX’s Belantamab Mafodotin for Heavily Treated Myeloma appeared first on BioNewsFeeds.